Positive FDA feedback and a strengthened balance sheet position the company for key clinical milestones in H2 2026, including pivotal data for amsulostat, SNT-4728, and SNT-9465. Recent capital raise extends cash runway into FY28.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.